Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET

Company Participants

Tram Bui - Vice President, Investor Relations and Corporate Communications

Dr. Helen Torley - President and CEO

Nicole LaBrosse - Chief Financial Officer

Conference Call Participants

Mohit Bansal - Wells Fargo

Mike DiFiore - Evercore ISI

Jason Butler - JMP Securities

Jessica Fye - JPMorgan

Corinne Jenkins - Goldman Sachs

Vikram Purohit - Morgan Stanley

Dan Tarjan - SVB Securities

Operator

Good afternoon. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme Fourth Quarter and Full Year 2022 Financial and Operating Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. [Operator Instructions]

Please note that this event is being recorded. I will now turn the call over to Tram Bui, Halozyme’s Vice President of Investor Relations and Corporate Communications. Please go ahead.

Tram Bui

Thank you, Operator. Good afternoon. And welcome to our fourth quarter and full year 2022 financial and operating results conference call. In addition to our press release issued today after the market close, you could find a supplementary slide presentation that will be referenced during today’s call in the Investor Relations section of our website.

Leading the call will be Dr. Helen Torley, Halozyme’s President and Chief Executive Officer, who will provide an update on our business; and Nicole LaBrosse, our Chief Financial Officer, who will review our financial results for the fourth quarter and full year 2022, as well as guidance for 2023.

On today’s call, we will be making forward-looking statements. I refer you to our SEC filings for a full list of risk and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.

I will now turn the call over to Helen Torley.

Dr. Helen Torley

Thank you, Tram, and good afternoon, everyone. I am very pleased with our fourth quarter and full year 2022 results, which continues to reflect strong financial and operational performance across the entire company, creating positive momentum and positioning Halozyme for an exciting 2023.

In 2022, we extended our leadership as a subcutaneous drug delivery platform company through the continued expansion and progress of our ENHANZE portfolio and through the acquisition of Antares Pharma and the small volume auto-injector platforms. The acquisition also resulted in a diversification of our revenues with the addition of the auto-injector and specialty to software and products businesses.